ReGenX Biosciences
NASDAQ: RGNX
Advancing AAV-based treatments for rare genetic diseases through gene therapy.
Sector
Life SciencesCategory
TherapeuticsLocation
Washington, D.C.Initial Investment
2013
Advancing AAV-based treatments for rare genetic diseases through gene therapy.
ReGenX Biosciences (NASDAQ: RGNX) is a leading AAV (adeno-associated virus) gene therapy company with a broad platform technology based on its proprietary NAV vector technology platform.